FTRE — Fortrea Holdings Inc.

Fortrea (FTRE) Q4 and Full Year 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $660.5 million, down 5.2% year-over-year, primarily due to lower pass-through costs.
• Full Year Revenue: $2.723 billion, up 1% year-over-year, driven by growth in Clinical Pharmacology.
• Adjusted EBITDA: Q4 at $54 million, down from $56 million year-over-year; full year at $189.9 million.
• Net Loss: Q4 net loss of $32.5 million, improved from a loss of $73.9 million in the prior year.
• Book-to-Bill Ratio: Q4 at 1.14x, trailing 12-month at 1.02x; backlog at $7.7 billion.
• Cash Flow: Positive operating cash flow of $129.1 million and free cash flow of $121.6 million in Q4; full year operating cash flow at $113.5 million.

2. Strategic Updates and Business Highlights

• Cost Savings: Achieved $153 million in gross savings and $93 million in net savings for the year, exceeding targets.
• Leadership Changes: Expanded leadership team with key appointments, including Aggie Gallagher as General Counsel and Dr. Scott Dave for clinical pharmacology.
• Operational Excellence: Focused on improving project management and client experience, with investments in AI and technology to enhance efficiency.
• Client Engagement: Increased engagement levels and improved client satisfaction, as indicated by a higher Net Promoter Score.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Targeting $2.55 billion to $2.65 billion, reflecting anticipated headwinds in FSP and pass-through costs.
• Adjusted EBITDA Guidance: Expected between $190 million and $220 million.
• Cost Reduction Goals: Continuing efforts to achieve an additional $70 million to $80 million in gross savings in 2026.
• Cash Flow Expectations: Anticipating positive operating cash flow for the full year despite a negative first quarter due to variable compensation payouts.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Q4 revenue decline attributed to lower pass-through costs and continued FSP headwinds.
• FSP Revenue Challenges: Ongoing difficulties in the Full-Service Provider segment impacting overall growth.
• Market Conditions: Cautious macroeconomic environment with uneven recovery expected in early 2026.
• Customer Concentration: Top 10 customers accounted for 56.8% of revenue, raising concerns about dependency on a limited client base.

5. Notable Q&A Insights

• Market Outlook: CEO Anshul Thakral expressed cautious optimism about market recovery, particularly in biotech, with improved client engagement and decision-making timelines.
• Bookings Mix: Positive trends in full-service bookings, with a strategic focus on reducing reliance on FSP due to margin pressures.
• AI Impact: AI viewed as a productivity enhancer rather than a replacement for CRO roles; discussions with clients indicate a cautious approach to AI adoption.
• Customer Retention and Growth: Emphasis on executive-led engagements to enhance relationships with new clients, showing positive trends in RFP flow from biotech.

Overall, Fortrea's performance in Q4 and full year 2025 reflects a mix of solid execution against strategic initiatives and ongoing challenges in revenue growth and market conditions. The company is positioned for cautious optimism in 2026, focusing on operational improvements and cost management.